| Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. | |
| | |
MedLine Citation:
|
PMID: 15588748 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Aripiprazole is a new atypical antipsychotic with a mode of action that is distinct from currently available antipsychotic drugs. In phase III comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy. Consistent with an atypical profile, aripiprazole is effective against positive, negative and cognitive symptoms of schizophrenia and has a favourable side effect profile with the incidence of extrapyramidal symptoms (EPS) comparable to placebo. It is also devoid of side effects such as clinically significant hyperprolactinaemia, hypercholesterolaemia and cardiotoxicity, and has a low propensity for weight gain. Symptom relief is achieved without significant sedation. These clinical data suggest its usefulness in psychosocial rehabilitation, as well as in long-term prevention of schizophrenic relapse. Recent results from a multicentre, open-label study in a general psychiatric setting provide the first evidence that aripiprazole is also effective under naturalistic conditions. However, only post-marketing experience will show whether the positive results of these controlled trials can be replicated in everyday practice. |
| | |
Authors:
|
Dieter Naber; Martin Lambert |
Related Documents
:
|
16880478 - Aripiprazole for schizophrenia. systematic review. 16316478 - A meta-analysis of profile and time-course of symptom change in acute schizophrenia tre... 15554768 - A retrospective analysis of quetiapine in the treatment of pervasive developmental diso... 12418608 - Amisulpride: progress and outcomes. 20511208 - Migraine recurrence is not associated with depressive or anxiety symptoms. results of a... 23633658 - Dry eye syndrome, posttraumatic stress disorder, and depression in an older male vetera... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Progress in neuro-psychopharmacology & biological psychiatry Volume: 28 ISSN: 0278-5846 ISO Abbreviation: Prog. Neuropsychopharmacol. Biol. Psychiatry Publication Date: 2004 Dec |
Date Detail:
|
Created Date: 2004-12-13 Completed Date: 2005-03-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8211617 Medline TA: Prog Neuropsychopharmacol Biol Psychiatry Country: England |
Other Details:
|
Languages: eng Pagination: 1213-9 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry and Psychotherapy, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany. naber@uke.uni-hamburg.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
pharmacology,
therapeutic use* Clinical Trials, Phase III as Topic Haloperidol / therapeutic use Humans Meta-Analysis as Topic Piperazines / pharmacology, therapeutic use* Quinolones / pharmacology, therapeutic use* Risperidone / therapeutic use Schizophrenia / drug therapy* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Piperazines; 0/Quinolones; 106266-06-2/Risperidone; 129722-12-9/aripiprazole; 52-86-8/Haloperidol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: On the generation and ownership of alpha in medical studies.
Next Document: Dopamine and alcoholism: neurobiological basis of ethanol abuse.